Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.60 |
| ▸ | HTR2A | P28223 | 12/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3951463 | 0.92 | SLC6A4 (0.61) | SLC6A4HRH3SLC6A2SLC6A3HTR2A | |
| SCHEMBL3943015 | 0.85 | SLC6A4 (0.66) | SLC6A4HRH3SLC6A2SLC6A3HTR2A | |
| SCHEMBL4012270 | 0.83 | SLC6A4 (0.61) | SLC6A4HRH3SLC6A2SLC6A3HTR2A | |
| SCHEMBL4017870 | 0.82 | SLC6A4 (0.53) | SLC6A4HRH3SLC6A2SLC6A3HTR2A | |
| SCHEMBL4019345 | 0.81 | HRH3 (0.43) | SLC6A4HRH3SLC6A2SLC6A3HTR2A | |
| SCHEMBL3943608 | 0.79 | SLC6A4 (0.52) | SLC6A4HRH3SLC6A2SLC6A3HTR2A | |
| SCHEMBL3950598 | 0.79 | SLC6A4 (0.63) | SLC6A4HRH3SLC6A2SLC6A3HTR2A | |
| SCHEMBL3950804 | 0.77 | SLC6A4 (0.63) | SLC6A4HRH3SLC6A2SLC6A3HTR2A | |
| SCHEMBL3947165 | 0.77 | SLC6A4 (0.68) | SLC6A4HRH3SLC6A2SLC6A3HTR2A | |
| SCHEMBL3949020 | 0.75 | SLC6A4 (1.00) | SLC6A4HRH3SLC6A2SLC6A3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137562-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-28 | — | — | US | claimed |
| US-7479493-B2 | Substituted benzyl amine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-20 | — | — | US | claimed |
| US-20080045509-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | claimed |
| US-20090137562-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137562-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137562-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-28 | — | — | US | disclosed |
| EP-2049473-A2 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-22 | — | — | EP | disclosed |
| US-7479493-B2 | Substituted benzyl amine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-20 | — | — | US | disclosed |
| US-7479493-B2 | Substituted benzyl amine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-20 | — | — | US | disclosed |
| US-7479493-B2 | Substituted benzyl amine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-20 | — | — | US | disclosed |
| US-20080045509-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045509-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045509-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| WO-2008002820-A2 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008002820-A2 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045509-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | HRH3, HNMT, HRH4 | SLC6A4 8/4885HRH3 1/4885SLC6A2 17/4885 |
| US-20090137562-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | HRH3, HNMT, HRH4 | SLC6A4 8/4885HRH3 1/4885SLC6A2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.